NMSP binding to dopamine and serotonin receptors in MPTP-induced parkinsonism: Relation to dopa therapy

Acta Neurologica Scandinavica

Volumn 100, Issue 1, 1999, Pages 42-52

  Borbely, K ^a   Brooks, R A ^a   Wong, D F ^d   Burns, R Stanley ^b   Cumming, P ^d   Gjedde, Albert ^c   Di Chiro, G ^a  

^a Neuroimaging Branch   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d NONE

Author keywords

Dopamine; Hoehn and Yahr staging; L dihydroxyphenylalanine (L dopa); N methyl phenyltetrahydro pyridine (MPTP); N methylspiperone (NMSP) binding; Parkinsonism; Positron emission tomography (PET)

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 METHYLSPIPERONE; DOPAMINE; DOPAMINE RECEPTOR; SEROTONIN RECEPTOR;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; DEPRESSION; DETERIORATION; DOPAMINE RECEPTOR BLOCKING; DRUG CLEARANCE; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; HUMAN; MALE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; RECEPTOR DENSITY;

EID: 0033009121     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1999.tb00722.x     Document Type: Article

References (44)

1. 1. Perlmutter JS, Kilbourn MR, Raichle ME, Welch MJ. MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding in humans. Neurology 1987;37:1575-9.
2. 2-receptors. Neurology 1994;44:1325-9.
3. 11C]raclopride binding in rat striatum, quantified using PET. Synapse 1995;21:45-53.
4. 2 dopamine receptors in rat striatum, measured using in vivo microdialysis and PET. J Neural Transm 1998;105:349-64.
5. 5. Rozas G, Liste I, Guerra MJ, Labandeira-Garcia JL. Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci Lett 1998;245:151-4.
6. 6. Brooks WJ, Jarvis MF, Wagner GC. Attenuation of MPTP-induced dopaminergic neurotoxicity by a serotonin uptake blocker. J Neural Transm 1988;71:85-90.
7. 3H]dopa in the telencephalon of the living rat. Brain Res 1997;747:60-9.
8. 8. Wong DF, Gjedde A, Wagner HN Jr. Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands. J Cereb Blood Flow Metab 1986;6:137-46.
9. 9. Burns RS, Dewitt RA, Ebert MH, Pakkenberg H, Kopin IJ. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 1985;312:1418-21.
10. 10. Haase HJ. The purely neuroleptic effect and its relation to the "neuroleptic threshold". Acta Psychiatr Belg 1978;78:19-36.
11. 11. Sank VJ, Brooks RA, Friauf WS, Leighton SB, Cascio HE, Dichiro G. Performance evaluation and calibration of the Neuro-PET scanner. IEEE Trans Nucl Sci 1983;30:636-9.
12. 12. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease. Neurology 1998;51:1075-80.
13. 13. Gjedde A, Wong DF. Reference region model of irreversible ligand binding. NeuroImage 1998;7(Part 3):A23.
14. 2 dopamine receptors in drug-naive schizophrenics. Science 1986;234:1558-63.
15. 11C]raclopride. Arch Gen Psychiatry 1990;47:213-19.
16. 11C-N-methylspiperone. Psychiatry Res 1993;49:219-37.
17. 17. Seeman P, Ulpian C, Bergeron C et al. Bimodal distribution of dopamine receptor densities in brain of schizophrenics. Science 1984;225:728-31.
18. 3H-Spiperone binding in normal and schizophrenic post-mortem human brain. Life Sci 1978;23:527-32.
19. 2 sites in Parkinson syndrome of different etiology. Brain Res 1989;483:30-8.
20. 3H]Spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur J Pharmacol 1984;99:167-75.
21. 2 receptor density remains constant in treated Parkinson's disease: Ann Neurol 1986;19:487-92.
22. 22. Lee T, Seeman P, Rajput A, Farley I, Hornykiewicz O. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature (Lond.) 1978;278:59-61.
23. 3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in Shy-Drager syndrome and Parkinson's disease. J Neurol Sci 1979;43:429-37.
24. 24. Reisine TD, Fields JC, Yamamura HI. Neurotransmitter receptor alterations in Parkinson's disease. Life Sci 1977;21:335-43.
25. 25. Rinne U, Lonnberg P, Koskinen V. Dopamine receptors in the parkinsonian brain. J Neurol Transm 1981;51:97-106.
26. 26. Rinne U, Rinne JO, Rinne JK, Laakso K, Laihinen A, Lonnberg P. Brain receptor changes in Parkinson's disease in relation to the disease process and treatment. J Neurol Transm 1983;16 (Suppl.)279-86.
27. 27. Rutgers AWP, Lakke JP, Paans AMJ, Vaalburg W, Korf J. Tracing of dopamine receptors in hemiparkinsonism with positron emission tomography (PET). J Neurol Sci 1987:80:237-48.
28. 28. Schneider M, Murrain L, Pfeiffer R, Deupree J. Dopamine receptors: Effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease. Clin Neuropharmacol 1984; 7:247-57.
29. 29. Reches A, Wagner HN, Jackson-Lewis V, Yablonskaya-Alter E, Fahn S. Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum. Neurology 1984;34:1208-12.
30. 30. Suga M. Effect on long-term L-dopa administration on the dopaminergic and cholinergic (muscarinic) receptors of striatum in 6-hydroxydopamine lesioned rats. Life Sci 1980;27:878-83.
31. 31. Thurkauf A, Yuan J, Chen X et al. 1-Phenyl-3-(aminomethyl)pyrroles as potential antipsychotic agents. Synthesis and dopamine receptor binding. J Med Chem 1995;38:4950-2.
32. 2 dopamine receptors: Visualization of cellular expression patterns in motor and limbic structures. Synapse 1995 ;20:325-7.
33. 3 analogs featuring aromatic and heteroaromatic rings: Design, synthesis and preliminary biological testing. J Med Chem 1995;38:4529-37.
34. 2 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl) 1995;120:365-8.
35. 35. Arnett CD, Shiue CY, Wolf AP, Fowler JS, Watanabe M. Comparison of three 18F labeled butyrophenone neuroleptic drugs in the baboon using positron emission tomography. J Neurochem 1985;44:835-44.
36. 18F-N-methylspiroperidol: the radioligand of choice for PET-studies of the dopamine receptors in human brain. Life Sci 1985;36:1359-66.
37. 37. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MT. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984;15:217-27.
38. 38. Nomura H. Clinical experience with spiperone. Clin Med 1973;10:3-10.
39. 39. Inoue Y, Wagner HN, Wong DF et al. Atlas of dopamine receptor images (PET) of the human brain. J Comput Assist Tomogr 1985;9:129-40.
40. 40. Wong DF, Gjedde A, Wagner HN Jr et al. Quantification of neuroreceptors in the living human brain. II. Inhibition studies of receptor density and affinity. J Cereb Blood Flow Metab 1986;6:147-53.
41. 11C-N-methyl-spiperone. Acta Neurol Scand 1987;75:87-94.
42. 2, receptor binding. J Neural Transm 1990;79:215-26.
43. max using high and low specific activity (C-II)NMSP and a unified estimation procedure. J Nucl Med 1991;32:1008.
44. 2-like receptors in caudate nucleus. NeuroImage 1997;5 (Part 3):A44.